In 1954, substances that protected cells from viral infection were discovered and named IFN (interferon). This family of cytokines, which were the first to be used in clinical therapy, is classified into type I and II IFNs. Type I mainly consists of IFNα and IFNβ subtypes, which are structurally related and bind to a common receptor. IFNγ , the sole type II IFN, is structurally unrelated, binds to a different receptor and, as a dimer, strongly interacts with HS (heparan sulphate). In addition to its antiviral activity, it modulates nearly all phases of immune and inflammatory responses. IFNγ binding to HS controls the blood clearance, the subsequent tissue targeting and the local accumulation of the cytokine. It also regulates IFNγ activity by a unique mechanism involving a controlled processing of the C-terminal peptide. The binding site encompasses an N-acetylated glucosamine-rich domain separating two highly sulphated sequences that each binds to one IFNγ monomer. Based on this template, a set of glycoconjugate mimetics that would mimic the IFNγ binding site has been synthesized. One of these molecules displays high affinity for the cytokine and inhibits binding to both HS and IFNγ R (IFNγ receptor), the cell-surface receptor. These results validate the HS structural determinants for IFNγ recognition, and provide a new strategy to inhibit IFNγ in a number of diseases in which the cytokine has been identified as a target.
Introduction
Cytokines are a family of relatively small size and soluble proteins that mediate cell-to-cell communication. They are released primarily, but not exclusively, by cells of the immune system, and play vital roles in the regulation of an extraordinarily large number of processes. The cytokine research field started in the early 1950s with IFN (interferon) the first cytokine to be discovered when it was observed that tissue extracts from viral-infected animals, inactivated by UV irradiation, had a protective activity against a viral challenge [1] . These observations suggested the presence of factors in the tissue extract, which, based on their ability to interfere with viral replication, were named IFN [2] . Since that discovery, IFN research has led to many breakthroughs: in addition to being the first known cytokine, it was the first cytokine recombinantly expressed, the first used in clinical therapy, and the cytokine that led to discovery of a unique signal transduction pathway, the JAK (Janus kinase)/STAT (signal transducer and activator of transcription) pathway.
IFNs are now classified into type I and type II, according to receptor specificity and sequence homology [3] . The type I comprises multiple IFNα subtypes, IFNβ, IFNδ, IFNε, IFNκ, IFNτ and IFNω, all of which are structurally related and bind to a common heterodimer receptor. IFNγ is the sole type II IFN. It is structurally unrelated to type I IFNs, binds to a different receptor, is encoded by a separate chromosomal locus and also interacts with HS (heparan sulphate) [4] . Although IFNγ displays most of the biological activities that have been ascribed to type I IFN, it has a lower specific antiviral activity, but is much more active as an immunomodulator. Thus, while IFNα/β are primarily antiviral agents which display some immunomodulatory activities, IFNγ is primarily an immunomodulator that also exerts some antiviral activity.
IFNγ
IFNγ is a single-chain protein consisting of 143 amino acids (in human) and has a molecular mass of 17 kDa. The IFNγ molecule is organized as a homodimer, in which the two subunits are non-covalently associated in an antiparallel orientation, thereby leading to a juxtaposition of the N-and Cterminal portions of the opposing polypeptide chains. Each chain is made of six α-helices linked by short unstructured loop regions. The X-ray crystallographic analysis of the protein failed to reveal the structure of the C-terminal domain of the molecule which was believed to be disordered or at least highly flexible, and to extend away from the protein core [5] .
IFNγ is induced by a unique set of stimuli (either antigenic or mitogenic stimulations) and is primarily produced by NK cells (natural killer cells), cytotoxic CD8+ T-cells and the Th1 subset of T helper cells. Although IFNγ is active on all cells, mice with disrupted IFNγ genes essentially showed a set of subtle failures in immune function that became explicit when the mice were challenged with infectious agents. This indicates that IFNγ is involved primarily in mounting an immune response: IFNγ mainly promotes the activity of the components of the cell-mediated immune system such as macrophages, NK cells and cytotoxic T-cells. It also induces the production of MHC-I and MHC-II molecules, stimulates the differentiation of T4-lymphocytes into Th1 cells and inhibits the proliferation of Th2 cells. It helps regulate B-cell differentiation and stimulates the production of IgG subclasses that activate the complement pathway and promote opsonization. IFNγ is thus involved in both innate and adaptive immunity, and modulates the activity of virtually every component of the immune system [6] . However, it is also active in the regulation of matrix biosynthesis and tissue remodelling, and in cell adhesion, differentiation and proliferation [7] . It has been found that at least 200 genes are regulated upon IFNγ stimulation. A number of these genes correspond to transcription factors, which in turn can regulate the expression of other genes [8] , thus explaining the extraordinary pleiotropicity of this cytokine.
IFNγ has two ligands
The cell-surface signalling receptor: IFNγ R (IFNγ receptor)
IFNγ signals cells through an interaction with a specific receptor (IFNγ R). Consistently with the broad activities the cytokine displays, it is ubiquitously found on most if not all cells, including platelets [9] . This receptor consists of a ligand-binding chain (or IFNγ Rα) that exhibits an affinity for the cytokine in the low nanomolar range (K d = 0.1-1 nM) and which is expressed at a level of 500-20 000 binding sites per cell. The α chain is constitutively associated with another transmembrane protein (called IFNγ Rβ), that plays a minor role in binding the cytokine, but which is absolutely required for signalling [10] .
Both IFNγ R chains are devoid of intrinsic kinase/phosphatase activity; however, the IFNγ Rα and IFNγ Rβ intracellular domains contain binding motifs for the JAK1 and JAK2 respectively. Signal transduction starts with an interaction of the IFNγ homodimer with two α chains, thereby inducing dimerization. The consequent association of the two β chains with the IFNγ -IFNγ Rα chain complex leads to crossphosphorylation of JAK1 and JAK2 that become activated and subsequently phosphorylate a tyrosine residue on each IFNγ Rα. This forms two juxtaposed docking sites for the latent cytosolic factor, STAT1. Receptor-docked STAT1 are phosphorylated by the JAK, then dissociate from the receptor and form a homodimer that translocates to the nucleus where it activates IFNγ -regulated genes [3, 11] .
IFNγ structural elements required for receptor binding have been determined [12] . They are located in three distinct areas of the cytokine: the loop connecting the first two helices (residues 18-26), the His 111 and a short section of the flexible C-terminus (residues 128-131). The structure of IFNγ in complex with IFNγ Rα clearly showed, at the molecular level, how these two first domains interact with the receptor. Unfortunately, as for the structure of the unliganded cytokine, the C-terminal domain co-ordinates remained undefined [13] . However, numerous studies have been dedicated to the significance of this domain for the biological activity of IFNγ [14] , and its importance has been well defined. The C-terminal domain (downstream of amino acids 124) is enriched in basic residues (three lysine and five arginine residues). This part of the molecule, which is a regulatory element of the cytokine activity, is particularly sensitive to a variety of proteases. As a consequence, native IFNγ is usually a mixture of carboxyl truncated molecules lacking up to 16 amino acids, and therefore may end anywhere from Gln 143 (fulllength molecule) to Gly 127 . Since deletion of less than ten amino acids increases the bioactivity of IFNγ , whereas a more extended cleavage of the C-terminal domain has the opposite effect, it has been proposed that the cytokine activity could be modulated by limited proteolysis. The portion of the C-terminus that appeared to be the most important in this process is a basic sequence KRKR (amino acids 128-131) since the beginning of its removal correlated with loss of activity, while cleavage downstream of this sequence resulted in the observed increase in activity [15] .
HS
Initial observations that IFNγ strongly associated with basement membrane led to the identification of HS proteoglycan as a new ligand of the cytokine. The binding site was found on the glycosaminoglycan chain, and is characterized by a relatively high affinity (K d = 5 nM) [16] . IFNγ comprises four basic clusters of amino acids (KLFKNFK, KKKR, KTGKRKR and RGRR) that could potentially all function as HS/heparin binding sequences. However, it was found that the binding activity entirely relies on the two last domains (KTGKRKR and RGRR), both contained within the Cterminal peptide of the cytokine [17] .
In vivo studies showed that IFNγ binding to HS controls the blood clearance, the subsequent tissue targeting, and the local accumulation of the cytokine. Furthermore, the binding of heparin to IFNγ limits the extent of its C-terminal domain degradation to less than ten amino acids, a process that, as indicated above, strongly increases the cytokine activity, while unliganded IFNγ is rapidly inactivated by an extensive C-terminal processing [18, 19] . These observations suggest a mechanism by which IFNγ is rapidly captured and activated by HS in the vicinity of the secreting cells, thus ensuring a localized action of the cytokine, while unbound IFNγ is inactivated, thus preventing cell stimulation by diffusing cytokines.
The structural organization of the HS domain that binds to IFNγ has been investigated. IFNγ -affinity chromatography of HS oligosaccharides first showed that the binding site is not found in domains released by either enzymatic or chemical cleavage of the chain. A footprinting approach in which HS was depolymerized in the presence of IFNγ gave rise to a protected sequence that retained the binding activity of the full-length polysaccharide. This fragment was composed of an extended internal domain that was predominantly Nacetylated and GlcA-rich (NA domain), flanked by two small N-sulphated oligosaccharides (mainly hexa-to octa-saccharides, or NS domains). This was the first description of an HS protein-binding sequence with this type of molecular organization [20] , and this has been observed since then for a number of other proteins, including PDGF (platelet-derived growth factor), IL-8 (interleukin-8), MIP (macrophage inflammatory protein), RANTES (regulated upon activation, normal T-cell expressed and secreted) and endostatin [21] [22] [23] [24] [25] . As IFNγ was known to be a homodimer, a model of the complex was proposed, in which the two sulphated terminal sequences of the binding domain interact directly with the two IFNγ C-termini and bridge the two cytokine monomers through the internal N-acetyl-rich sequence.
Mimicking the IFNγ -binding site in HS
The structural complexity and size of the IFNγ -binding oligosaccharide hampered its isolation in pure form and in sufficiently large amounts. This prevents the further analysis of the structure-function relationship of the IFNγ -HS complex. Thus, in order to both validate the proposed model and to obtain homogeneous material in large quantity, a strategy was adopted by which the binding domain would be produced by chemical synthesis. As suggested by the model, the internal NA region may not interact directly with the cytokine, but rather spaces apart the two external NS domains to present them in front of the two IFNγ C-termini. A strategy was thus designed, in which two NS domains were linked to each other through a poly(ethylene glycol)-based linker of appropriate length. This was developed by David Bonnaffé at the Orsay University in Paris [26] , and a set of compounds called 2X n was obtained (in which 2 means that two oligosaccharides X are linked through a spacer having n ethylene glycol repeats). This strategy was successful, and among the different 2X n molecules synthesized, 2O 10 (O stands for octasaccharide) very efficiently interacted with the cytokine, inhibited the IFNγ -heparin interaction with an IC 50 of 35-40 nM and, thus, appeared as a good mimic of the IFNγ -binding domain [27] .
Further developments
The achievement of such a molecule has a number of different interests. A possibility that arises from that is to develop structural studies of the cytokine in complex with the 2O 10 glycoconjugate, a point that was not possible before. In particular, the C-terminal peptide of IFNγ may fold upon binding to its target and thus might be characterized by X-ray crystallography. Because this part of the protein is a critical regulatory element of the cytokine activity, resolving its structure remains an important issue. On the oligosaccharide side, the sulphation profile within the NS-octasaccharides has not been addressed yet. This could now be investigated in the context of the 2O 10 scaffold, using combinatorial synthesis as a possible tool to generate distinct sulphoforms and/or iduronic/glucuronic patterns.
Finally, we also reported that 2O 10 inhibited the binding of IFNγ to the IFNγ Rα chain, and consequently the biological activity of the cytokine [27] . This important observation thus provides a new strategy to inhibit IFNγ in a number of diseases, in which the cytokine has been identified as an attractive target. IFNγ is a key cytokine involved in the development and maintenance of the Th1 arm of the immune system. However, aberrant expression of IFNγ in transgenic mice under the control of various tissue-specific promoters generates sites of inflammation with subsequent severe tissue destruction, and it is well described that aside from normal functions in host defence, IFNγ production may also contribute to a number of diseases characterized by pro-inflammatory and auto-aggressive Th1 response [28, 29] . These include autoimmune pathologies, or chronic inflammatory bowel diseases. IFNγ is also a key contributor to hyperoxiainduced lung injury and, due to its ability to induce MHC in many tissues, is associated with graft rejection. Future works will aim at investigating whether 2O 10 -or 2O 10 -related compounds could provide benefits in such diseases. Since these molecules can both delocalize the cytokine from cellsurface-associated HS and prevent binding to the signalling receptor, they might be much more efficient than neutralizing antibody, selected on their ability to block binding to IFNγ R, but not to HS [30] . This work, among others, further shows that understanding HS-protein interaction at the molecular level could lead to the design of molecules with possible therapeutic activity.
